Obstet Gynecol Sci.  2021 May;64(3):239-247. 10.5468/ogs.20345.

Placenta accreta spectrum-a catastrophic situation in obstetrics

• Pegu B
• Thiagaraju C
• Nayak D
• Subbaiah M

• KMID: 2515975
• DOI: http://doi.org/10.5468/ogs.20345

Abstract

Placenta accreta is a significant obstetric complication in which the placenta is completely or focally adherent to the myometrium. The worldwide incidence of placenta accreta spectrum (PAS) is increasing day by day, mostly due to the increasing trends in cesarean section rates. The accurate and timely diagnosis of placenta accreta is important to improve the feto-maternal outcome. Although standard ultrasound is a reliable and primary tool for the diagnosis of placenta accreta, the absence of ultrasound findings does not preclude the diagnosis of placenta accreta. Therefore, clinical evaluation of risk factors is equally essential for the prediction of abnormal placental invasion. Pregnant women with a high impression or established diagnosis of placenta accreta should be managed by a multidisciplinary team in a specialist center. Traditionally, PAS has been managed by an emergency obstetric hysterectomy. Previously, few studies suggested a satisfactory success rate of conservative management in well-chosen cases, whereas few studies recommended delayed hysterectomy to reduce the amount of bleeding. The continuously increasing trends of PAS and the challenges for its routine management are the main motives behind this literature review.

Keyword

Placenta accreta spectrum; Massive hemorrhage; Maternal morbidity; Obstetric hysterectomy

Reference

References

1. Jauniaux E, Chantraine F, Silver RM, Langhoff-Roos J; for the FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on placenta accreta spectrum disorders: epidemiology. Int J Gynecol Obstet. 2018; 140:265–73.

2. Mittal P, Suri J, Pruthi N, Pandey D, Bharti R. Comparison of placenta accreta spectrum disorders diagnosed in intrapartum and antepartum period-a three year experience in a tertiary referral unit of India. Eur J Obstet Gynecol Reprod Biol. 2019; 236:41–5.

3. Solheim KN, Esakoff TF, Little SE, Cheng YW, Sparks TN, Caughey AB. The effect of cesarean delivery rates on the future incidence of placenta previa, placenta accreta, and maternal mortality. J Matern Fetal Neonatal Med. 2011; 24:1341–6.

4. Fitzpatrick KE, Sellers S, Spark P, Kurinczuk JJ, Brocklehurst P, Knight M. The management and outcomes of placenta accreta, increta, and percreta in the UK: a population-based descriptive study. BJOG. 2014; 121:62–71.

5. Thurn L, Lindqvist PG, Jakobsson M, Colmorn LB, Klungsoyr K, Bjarnadóttir RI, et al. Abnormally invasive placenta- prevalence, risk factors and antenatal suspicion: results from a large population-based pregnancy cohort study in the Nordic countries. BJOG. 2016; 123:1348–55.

6. Bowman ZS, Eller AG, Kennedy AM, Richards DS, Winter TC 3rd, Woodward PJ, et al. Accuracy of ultrasound for the prediction of placenta accreta. Am J Obstet Gynecol. 2014; 211:177. e1-7.

7. Eller AG, Bennett MA, Sharshiner M, Masheter C, Soisson AP, Dodson M, et al. Maternal morbidity in cases of placenta accreta managed by a multidisciplinary care team compared with standard obstetric care. Obstet Gynecol. 2011; 117(2 Pt 1):331–7.

8. Shamshirsaz AA, Fox KA, Erfani H, Clark SL, Salmanian B, Baker BW, et al. Multidisciplinary team learning in the management of the morbidly adherent placenta: outcome improvements over time. Am J Obstet Gynecol. 2017; 216:612. e1-5.

9. Shamshirsaz AA, Fox KA, Erfani H, Clark SL, Shamshirsaz AA, Nassr AA, et al. Outcomes of planned compared with urgent deliveries using a multidisciplinary team approach for morbidly adherent placenta. Obstet Gynecol. 2018; 131:234–41.

10. Bailit JL, Grobman WA, Rice MM, Reddy UM, Wapner RJ, Varner MW, et al. Morbidly adherent placenta treatments and outcomes. Obstet Gynecol. 2015; 125:683–9.

11. Higgins MF, Monteith C, Foley M, O’Herlihy C. Real increasing incidence of hysterectomy for placenta accreta following previous caesarean section. Eur J Obstet Gynecol Reprod Biol. 2013; 171:54–6.

12. Silver RM, Landon MB, Rouse DJ, Leveno KJ, Spong CY, Thom EA, et al. Maternal morbidity associated with multiple repeat cesarean deliveries. Obstet Gynecol. 2006; 107:1226–32.

13. Miller DA, Chollet JA, Goodwin TM. Clinical risk factors for placenta previa-placenta accreta. Am J Obstet Gynecol. 1997; 177:210–4.

14. Garmi G, Salim R. Epidemiology, eitiology, diagnosis and management of placenta accreta. Obstet Gynecol Int. 2012; 2012:873929.

15. Baldwin HJ, Patterson JA, Nippita TA, Torvaldsen S, Ibiebele I, Simpson JM, et al. Antecedents of abnormally invasive placenta in primiparous women: risk associated with gynecologic procedures. Obstet Gynecol. 2018; 131:227–33.

16. Fitzpatrick KE, Sellers S, Spark P, Kurinczuk JJ, Brocklehurst P, Knight M. Incidence and risk factors for placenta accreta/increta/percreta in the UK: a national case-control study. PLoS One. 2012; 7:e52893.

17. Hayashi M, Nakai A, Satoh S, Matsuda Y. Adverse obstetric and perinatal outcomes of singleton pregnancies may be related to maternal factors associated with infertility rather than the type of assisted reproductive technology procedure used. Fertil Steril. 2012; 98:922–8.

18. Ishihara O, Araki R, Kuwahara A, Itakura A, Saito H, Adamson GD. Impact of frozen-thawed single-blastocyst transfer on maternal and neonatal outcome: an analysis of 277,042 single-embryo transfer cycles from 2008 to 2010 in Japan. Fertil Steril. 2014; 101:128–33.

19. Horcajadas JA, Riesewijk A, Polman J, van Os R, Pellicer A, Mosselman S, et al. Effect of controlled ovarian hyperstimulation in IVF on endometrial gene expression profiles. Mol Hum Reprod. 2005; 11:195–205.

20. Kaser DJ, Melamed A, Bormann CL, Myers DE, Missmer SA, Walsh BW, et al. Cryopreserved embryo transfer is an independent risk factor for placenta accreta. Fertil Steril. 2015; 103:1176–84. e2.

21. O’Brien JM, Barton JR, Donaldson ES. The management of placenta percreta: conservative and operative strategies. Am J Obstet Gynecol. 1996; 175:1632–8.

22. Ajah LO, Eze MI, Dim CC, Ezegwui HU, Nkwo PO, Eluke CC, et al. Placenta percreta in a booked multiparous woman with minimal risk factors and challenges of management in a low resource setting. Niger J Med. 2012; 21:359–60.

23. Jauniaux E, Jurkovic D. Placenta accreta: pathogenesis of a 20th century iatrogenic uterine disease. Placenta. 2012; 33:244–51.

24. Randall S, Buckley CH, Fox H. Placentation in the fallopian tube. Int J Gynecol Pathol. 1987; 6:132–9.

25. Godyn JJ, Hazra A, Gulli VM. Subperitoneal placenta accreta succenturiate in the case of a successful nearterm extrauterine abdominal pregnancy. Hum Pathol. 2005; 36:922–6.

26. Flo K, Widnes C, Vårtun Å, Acharya G. Blood flow to the scarred gravid uterus at 22-24 weeks of gestation. BJOG. 2014; 121:210–5.

27. Jauniaux E, Collins S, Burton GJ. Placenta accreta spectrum: pathophysiology and evidence-based anatomy for prenatal ultrasound imaging. Am J Obstet Gynecol. 2018; 218:75–87.

28. Fox H. Placenta accreta: 1945-1969. Obstet Gynecol Surv. 1972; 27:475–90.

29. Benirschke K, Burton GJ, Baergen RN. Pathology of the human placenta, 6th ed. Berlin: Springer-Verlag;2012.

30. Cahill AG, Beigi R, Heine RP, Silver RM, Wax JR; American College of Obstetricians and Gynecologists. Placenta Accreta Spectrum. Am J Obstet Gynecol. 2018; 219:B2–16.

31. Baughman WC, Corteville JE, Shah RR. Placenta accreta: spectrum of US and MR imaging findings. Radiographics. 2008; 28:1905–16.

32. Jauniaux E, Alfirevic Z, Bhide AG, Belfort MA, Burton GJ, Collins SL, et al. Placenta praevia and placenta accreta: diagnosis and management: green-top guideline no. 27a. BJOG. 2019; 126:e1–48.

33. D’Antonio F, Iacovella C, Bhide A. Prenatal identification of invasive placentation using ultrasound: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2013; 42:509–17.

34. D’Antonio F, Iacovella C, Palacios-Jaraquemada J, Bruno CH, Manzoli L, Bhide A. Prenatal identification of invasive placentation using magnetic resonance imaging: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2014; 44:8–16.

35. Reddy YS, Y A, Ramalakshmi BA, Kumar BD. Lead and trace element levels in placenta, maternal and cord blood: a cross-sectional pilot study. J Obstet Gynaecol Res. 2014; 40:2184–90.

36. Tinari S, Buca D, Cali G, Timor-Tritsch I, Palacios-Jaraquemada J, Rizzo G, et al. Systematic review and meta-analysis of posterior placenta accreta spectrum disorders: risk factors, histopathology and diagnostic accuracy. Ultrasound Obstet Gynecol. 2020; Aug. 25. [Epub]. https://doi.org/10.1002/uog.22183.

37. Meyer NP, Ward GH, Chandraharan E. Conservative approach to the management of morbidly adherent placentae. Ceylon Med J. 2012; 57:36–9.

38. American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 135: second-trimester abortion. Obstet Gynecol. 2013; 121:1394–406.

39. Silver RM, Barbour KD. Placenta accreta spectrum: accreta, increta, and percreta. Obstet Gynecol Clin North Am. 2015; 42:381–402.

40. Eller AG, Porter TF, Soisson P, Silver RM. Optimal management strategies for placenta accrete. BJOG. 2009; 116:648–54.

41. Warshak CR, Ramos GA, Eskander R, Benirschke K, Saenz CC, Kelly TF, et al. Effect of predelivery diagnosis in 99 consecutive cases of placenta accrete. Obstet Gynecol. 2010; 115:65–9.

42. Clark SL, Phelan JP, Yeh SY, Bruce SR, Paul RH. Hypogastric artery ligation for obstetric hemorrhage. Obstet Gynecol. 1985; 66:353–6.

43. Panigrahi AK, Yeaton-Massey A, Bakhtary S, Andrews J, Lyell DJ, Butwick AJ, et al. A standardized approach for transfusion medicine support in patient with morbidly adherent placenta. Anesth Analg. 2017; 125:603–8.

44. Committee on Practice Bulletins-Obstetrics. Practice bulletin no. 183: postpartum hemorrhage. Obstet Gynecol. 2017; 130:e168–86.

45. Simonazzi G, Bisulli M, Saccone G, Moro E, Marshall A, Berghella V. Tranexamic acid for preventing postpartum blood loss after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials. Acta Obstet Gynecol Scand. 2016; 95:28–37.

46. Chandraharan E, Rao S, Belli AM, Arulkumaran S. The triple-P procedure as a conservative surgical alternative to peripartum hysterectomy for placenta percreta. Int J Gynaecol Obstet. 2012; 117:191–4.

47. Teixidor Viñas M, Belli AM, Arulkumaran S, Chandraharan E. Prevention of postpartum hemorrhage and hysterectomy in patients with morbidly adherent placenta: a cohort study comparing outcomes before and after introduction of the triple-P procedure. Ultrasound Obstet Gynecol. 2015; 46:350–5.

48. Pinas-Carrillo A, Bhide A, Moore J, Hartopp R, Belli AM, Arulkumaran S, et al. Outcomes of the first 50 patients with abnormally invasive placenta managed using the “triple P procedure” conservative surgical approach. Int J Gynaecol Obstet. 2020; 148:65–71.

49. Sentilhes L, Kayem G, Chandraharan E, Palacios-Jaraquemada J, Jauniaux E. FIGO consensus guidelines on placenta accreta spectrum disorders: conservative management. Int J Gynecol Obstet. 2018; 140:291–8.

50. Ballas J, Hull AD, Saenz C, Warshak CR, Roberts AC, Resnik RR, et al. Preoperative intravascular balloon catheters and surgical outcomes in pregnancies complicated by placenta accreta: a management paradox. Am J Obstet Gynecol. 2012; 207:216. e1-5.

51. Tan CH, Tay KH, Sheah K, Kwek K, Wong K, Tan HK, et al. Perioperative endovascular internal iliac artery occlusion balloon placement in management of placenta accreta. AJR Am J Roentgenol. 2007; 189:1158–63.

52. Salim R, Chulski A, Romano S, Garmi G, Rudin M, Shalev E. Precesarean prophylactic balloon catheters for suspected placenta accreta: a randomized controlled trial. Obstet Gynecol. 2015; 126:1022–8.

53. Wu Q, Liu Z, Zhao X, Liu C, Wang Y, Chu Q, et al. Outcome of pregnancies after balloon occlusion of the infrarenal abdominal aorta during caesarean in 230 patients with placenta praevia accreta. Cardiovasc Intervent Radiol. 2016; 39:1573–9.

54. Wang YL, Duan XH, Han XW, Wang L, Zhao XL, Chen ZM, et al. Comparison of temporary abdominal aortic occlusion with internal iliac artery occlusion for patients with placenta accreta - a non-randomised prospective study. Vasa. 2017; 46:53–7.

55. Fox KA, Shamshirsaz AA, Carusi D, Secord AA, Lee P, Turan OM, et al. Conservative management of morbidly adherent placenta: expert review. Am J Obstet Gynecol. 2015; 213:755–60.

56. Sawada M, Matsuzaki S, Mimura K, Kumasawa K, Endo M, Kimura T. Successful conservative management of placenta percreta: investigation by serial magnetic resonance imaging of the clinical course and a literature review. J Obstet Gynaecol Res. 2016; 42:1858–63.